Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01129531 · ClinicalTrials.gov registry record · Phase 2

A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia

A Phase 2 study, sponsored by Allergan.

Completed
Registry status
Phase 2
Development phase
294
Enrollment target

NCT01129531: Completed Phase 2 study, sponsored by Allergan.

NCT01129531 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 294 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (121% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01129531, a Phase 2 study, has completed, sponsored by Allergan.

COMPLETED
Registry status
Phase 2
Development phase
294 participants
Enrollment target

Study Summary

This study will evaluate the safety and efficacy of AGN-214868 in patients with postherpetic neuralgia (PHN) - nerve pain.

Primary Outcome

Participants rated the severity of their daily pain in the previous 7 days using a 10 point scale where 0=no pain to 10=pain as bad as you can imagine. A negative change from Baseline indicated improvement.

Interventions

  • DRUG AGN-214868
  • DRUG Placebo to AGN-214868

Trial Details

FieldValue
Enrollment Target 294 participants
Start Date 2010-06
Est. Completion 2012-01
Phase Phase 2
Allergan

314 total trials

What the finished NCT01129531 record still lists

NCT01129531 is an interventional study that assigns participants to a tested intervention. The registered 294 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (121% higher).

The record links to 0 conditions, and to 2 interventions - of which AGN-214868 is the first listed.

NCT01129531 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01129531 about?

NCT01129531 is a clinical study titled "A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia". This study will evaluate the safety and efficacy of AGN-214868 in patients with postherpetic neuralgia (PHN) - nerve pain.

What is the current status of trial NCT01129531?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 294 participants. The study started on 2010-06. Estimated completion is 2012-01.

What interventions are being tested in trial NCT01129531?

The interventions under investigation include: AGN-214868 (DRUG), Placebo to AGN-214868 (DRUG).

Who is sponsoring clinical trial NCT01129531?

This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01129531's enrollment target sits among peer trials

294 190th of 2000 higher than 1,810 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05775159 · 294 participants · Phase 2

    Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

  • NCT06262113 · 294 participants · NA

    A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1

  • NCT06338865 · 294 participants · NA

    Short Title: Standard vs. Lower Pressure Pneumoperitoneum

  • NCT06395467 · 294 participants · NA

    Integrated Treatment for Enhancing Growth in Recovery During Adolescence

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01129531, the US trial registry maintained by the National Library of Medicine. NCT01129531 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.